Inhibition by calcium antagonism of circulating and renal endothelin in experimental congestive heart failure

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 278, Issue 1 47-1, 2000, Pages

  Wei, Chiming ^a   Burnett Jr , John C ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Calcium channel antagonist; Vasoconstrictor; Vasodilator

Indexed keywords

CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN; FELODIPINE; VASOCONSTRICTOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM ANTAGONISM; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOG; HEART OUTPUT; IMMUNOHISTOCHEMISTRY; INFERIOR CAVA VEIN OBSTRUCTION; KIDNEY CORTEX; KIDNEY MEDULLA; LUNG VASCULAR RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC VASCULAR RESISTANCE;

EID: 0033964064     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.2000.278.1.h263     Document Type: Article

References (28)

1. Biondi, M. L., B. Marasini, C. Bassani, and A. Agastoni. Increased plasma endothelin levels in patients with Raynaud's phenomenon. N. Engl. J. Med. 324: 1139-1140, 1991.
2. Cernacck, P., and D. J. Stewart. Immunoreactive endothelin in human plasma: marked elevations in patients in cardiogenic shock. Biochem. Biophys. Res. Commun. 161: 562-567, 1989.
3. Clavell, A. L., M. T. Mattingly, T. L. Stevens, A. Nir, R. S. Wright, L. L. Aarhus, D. M. Heublein, and J. C. Burnett, Jr. Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. J. Clin. Invest. 97: 1286-1292, 1996.
4. Cody, R. J., G. J. Haas, P. F. Binkley, Q. Capers, and R. Kelley. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85: 504-509, 1992.
5. Davis, J., and D. Howell. Mechanisms of fluid and electrolyte retention in experimental preparations in dogs. II. With thoracic inferior vena cava constriction. Circ. Res. 1: 171-178, 1953.
6. Hiroe, M., Y. Hirata, N. Fujita, S. Umezawa, H. Ito, M. Tsujino, A. Koike, A. Nogami, T. Takamoto, and F. Marumo. Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy. Am. J. Cardiol. 68: 1114-1115, 1991.
7. Kribbs, S. B., W. M. Merritt, M. J. Clair, R. S. Krombach, W. V. Houck, M. G. Dodd, and R. Mukherjee. Amlodipine monotherapy, angiotensin-converting enzyme inhibition, and combination therapy with pacing-induced heart failure. Hypertension 31: 755-765, 1998.
8. Lerman, A., B. S. Edwards, J. W. Halite, D. M. Heublein, S. M. Sandberg, and J. C. Burnett, Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N. Engl. J. Med. 325: 997-1001, 1991.
9. Lerman, A., F. Hildebrand, L. Aarhus, and J. C. Burnett, Jr. Endothelin has biological actions at pathophysiologic concentrations. Circulation 83: 1808-1814, 1991.
10. Letizia, C., F. Barilla, S. Cerci, A. De Ciocchis, S. Coassin, M. A. Mastroianni, C. D'Ambrosio, P. P. Campa, and D. Scavo. Plasma endothelin-1 concentrations in patients with coronary artery disease during stress test before and after nisoldipine administration. Acta Cardiol. 51: 165-172, 1996.
11. Liu, J. J., D. J. Casley, C. I. Johnston, and B. F. Buxton. Constrictor effect, receptors and peptide levels of endothelin-1 in human internal mammary artery and cultured endothelial cells: effect of calcium antagonists (Abstract). Aust. N. Z. J. Med. 23: 66, 1993.
12. Liu, J. J., D. Casley, J. Wojta, M. Gallicchio, R. Dauer, B. F. Ruxton, and C. I. Johnston. Reduction of endothelin levels by the dihydropyridine calcium antagonist nisoldipine and a "natural factor" in cultured human endothelial cells. J. Hypertens. 11: 977-982, 1993.
13. Loffler, B. M., S. Roux, B. Kalina, M. Clozel, and J. P. Clozel. Influence of congestive heart failure on endothelin levels and receptors in rabbits. J. Mol. Cell. Cardiol. 25: 407-416, 1993.
14. Margulies, K., F. Hildebrand, A., Lerman, M. Perrella, and J. C. Burnett, Jr. Increased endothelin in experimental heart failure. Circulation 82: 2226-2230, 1990.
15. Masaoka, H., R. Suzuki, Y. Hirata, T. Emori, F. Marumo, and K. Hirakawa. Raised plasma endothelin in aneurysmal subarachnoid hemorrhage. Lancet 2: 1402, 1989.
16. Messerli, F. H. What, if anything, is controversial about calcium antagonists? Am. J. Hypertens. 9: 177S-181S, 1996.
17. Miyauch, T., M. Yanagisawa, T. Tomizawa, Y. Sugishita, N. Suzuki, M. Fujino, R. Ajisaka, and K. Goto. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet 2: 53-54, 1989.
18. Saijonmaa, O., T. Nyman, and F. Fyhrquist. Endothelin-1 stimulates its own synthesis in human endothelial cells. Biochem. Biophys. Res. Commun. 188: 286-291, 1992.
19. Salto, Y., K. Nakao, M. Mukoyama, and H. Imura. Increased plasma endothelin level in patients with essential hypertension. N. Engl. J. Med. 322: 205, 1989.
20. Sakai, S., T. Miyauchi, T. Sakurai, Y. Kasuya, M. Ihara, I. Yamaguchi, K. Goto, and Y. Sugishita. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation 93: 1214-1222, 1996.
21. Sandok, E. K., A. Lerman, A. J. Stingo, M. A. Perrella, P. Gloviczki, and J. C. Burnett, Jr. Endothelin in a model of acute ischemic renal dysfunction: modulating action of atrial natriuretic factor. J. Am. Soc. Nephrol. 3: 196-202, 1992.
22. Shibouta, Y., N. Suzuki, A. Shino, H. Matsumoto, Z. Terashita, K. Kondo, and K. Nishikawa. Pathophysiological role of endothelin in acute renal failure. Life Sci. 46: 1611-1618, 1990.
23. Underwood, R. D., L. L. Aarhus, D. M. Heublein, and J. C. Burnett, Jr. Endothelin in thoracic inferior vena caval constriction model of heart failure. Am. J. Physiol. Heart Circ. Physiol. 263: H951-H955, 1992.
24. Wei, C., A. Lerman, R. J. Rodeheffer, C. G. A. McGregor, R. R. Brandt, S. Wright, D. M. Heublein, P. C. Kao, W. D. Edwards, and J. C. Burnett, Jr. Endothelin in human congestive heart failure. Circulation 89: 1580-1586, 1994.
25. Yanagisawa, M., A. Inoue, Y. Takuwa, Y. Mitusi, M. Kobayashi, and T. Masaki. The human preproendothelin-1 gene: possible regulation of endothelial phosphoinositide turnover signaling. J. Cardiovasc. Pharmacol. 13, Suppl. 5: S13-S17, 1989.
26. Yanagisawa, M., H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, Y. Mitsui, Y. Yazaki, K. Goto, and T. Masaki. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415, 1988.
27. Yanagisawa, M., and T. Masaki. Endothelin, a novel endothelium-derived peptide. Pharmacological activities, regulation and possible roles in cardiovascular control. Biochem. Pharmacol. 38: 1877-1883, 1989.
28. Yoshizumi M., H. Kurihara, T. Sugiyama, F. Takaku, M. Yanagisawa, T. Masaki, and Y. Yazaki. Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells. Biochem. Biophys. Res. Commun. 161: 859-864, 1989.